felbamate and Aura
felbamate has been researched along with Aura in 142 studies
Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.
felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied the efficacy of felbamate (FBM) in combination with valproic acid (VPA) in 13 patients with the Lennox-Gastaut syndrome and evaluated the contribution of each drug." | 9.09 | The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. ( Flamini, R; Gaillard, WD; Kelley, K; Ko, D; Malow, B; Reeves-Tyer, P; Siegel, H; Stertz, B; Theodore, WH, 1999) |
| "The objective of this study was to assess the psychiatric effects of the antiepileptic drug (AED) felbamate (FBM) in patients with epilepsy." | 9.08 | Felbamate monotherapy has stimulant-like effects in patients with epilepsy. ( Flamini, R; Ketter, TA; Ko, D; Malow, BA; Post, RM; Theodore, WH; White, SR, 1996) |
| "Felbamate (FBM, Felbatol/Taloxa), a new antiepileptic drug (AED), was tested in a placebo-controlled add-on design in 73 patients with therapy refractory Lennox-Gastaut syndrome." | 9.07 | Felbamate in the treatment of Lennox-Gastaut syndrome. ( Jensen, PK, 1994) |
| "Our patient's electrographic status epilepticus of sleep resolved after treatment with felbamate." | 7.81 | Successful Treatment of Electrographic Status Epilepticus of Sleep With Felbamate in a Patient With SLC9A6 Mutation. ( Coorg, R; Weisenberg, JL, 2015) |
| "To present our experience with felbamate therapy in children with drug-resistant epilepsy." | 7.80 | Efficacy and safety of felbamate in children with refractory epilepsy. ( Epstein, O; Gandelman-Marton, R; Heyman, E; Lahat, E; Levin, N, 2014) |
| "The antiepileptic drug felbamate has demonstrated efficacy against a variety of seizure types in the pediatric population, particularly seizures associated with Lennox-Gastaut syndrome." | 7.76 | Efficacy of felbamate in the treatment of intractable pediatric epilepsy. ( Chico, MS; Eggener, KA; Hecox, KE; Marcuccilli, CJ; O'Connor, SE; Roell Werner, R; Schwabe, MS; Zupanc, ML, 2010) |
| "We present an implementation of a method we previously reported allowing the newer antiepileptic drugs (AEDs) rufinamide (RFN) and zonisamide (ZNS) to be simultaneously determined with lamotrigine (LTG), oxcarbazepine's (OXC) main active metabolite monohydroxycarbamazepine (MHD) and felbamate (FBM) in plasma of patients with epilepsy using high performance liquid chromatography (HPLC) with UV detection." | 7.76 | Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy. ( Albani, F; Baruzzi, A; Candela, C; Contin, M; Mohamed, S; Riva, R, 2010) |
| "A very simple and fast method has been developed and validated for simultaneous determination of the new generation antiepileptic drugs (AEDs) lamotrigine (LTG), oxcarbazepine's (OXC) main active metabolite monohydroxycarbamazepine and felbamate in plasma of patients with epilepsy using high-performance liquid chromatography (HPLC) with spectrophotometric detection." | 7.73 | Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. ( Albani, F; Balboni, M; Baruzzi, A; Callegati, E; Candela, C; Contin, M; Riva, R, 2005) |
| "The aim of the study was to assess the efficacy and safety of felbamate (FBM) as add-on therapy in pediatric patients with severe uncontrolled seizures during a 3-year follow-up." | 7.71 | The long-term use of felbamate in children with severe refractory epilepsy. ( Cilio, MR; Kartashov, AI; Vigevano, F, 2001) |
| "Influence Felbamate on the cerebral bioelectric activity (EEG) in the group of 31 children (18 with syndrome Lennox-Gastaut, 13 with partial epilepsy) with refractory epilepsy was investigated." | 7.70 | [Preliminary assessment of felbamate effect on the cerebral bioelectrical activity in children with refractory epilepsy]. ( Kuszczak, B; Mazur, J; Pakszys, M; Rusek, G; Szamotulska, K, 2000) |
| "The behavioral effects of felbamate were assessed in 20 persons, (ages 2 to 19 years) who were participating in a compassionate plea protocol for children with Lennox-Gastaut syndrome." | 7.69 | Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). ( Coskey, JS; Gay, PE; Mecham, GF; Sadler, T; Thompson, JA, 1995) |
| "We prospectively investigated drug-induced headaches (HA) among 60 epileptic patients receiving felbamate (FBM)." | 7.69 | Felbamate-induced headache. ( Andriola, MR; Berdia, A; Ettinger, AB; Jandorf, L; Krupp, LB; Weisbrot, DM, 1996) |
| "The usefulness of felbamate (FBM) levels in managing epilepsy patients has not been determined." | 7.69 | Felbamate levels in patients with epilepsy. ( Harden, CL; Kutt, H; Trifiletti, R, 1996) |
| "Felbamate was compared with several antiepileptic drugs for protective effects in two rat models of status epilepticus." | 7.68 | Effects of felbamate and other anticonvulsant drugs in two models of status epilepticus in the rat. ( Diamantis, W; Gels, M; Gordon, R; Sofia, RD, 1993) |
| "Felbamate (FBM) pharmacokinetic parameters, safety and tolerability in the dose range of 1,200-6,000 mg/day were assessed in two open-label studies with similar designs." | 6.68 | Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy. ( Lyness, WH; Narang-Sachdeo, SK; Perhach, JL; Rosenberg, A; Sachdeo, R; Shumaker, RC, 1997) |
| "felbamate appears to be an effective new AED: the most adverse effects occurring during administration of FBM are mild to moderate gastrointestinal (nausea, vomiting and anorexia) and central nervous system (headache, sonnolence, diplopia, dizziness and insomnia) disturbances." | 6.68 | [Felbamate: a long-term study in subjects with refractory epilepsy]. ( De Romanis, F; Sopranzi, N, 1997) |
| "Felbamate was licensed in 1993 for use as adjunctive therapy or monotherapy in adults with partial or tonic-clonic seizures and as adjunctive therapy for children with the Lennox-Gastaut syndrome." | 6.39 | Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin. ( Laxer, KD, 1994) |
| "Felbamate (FBM) is an effective and safe novel antiepileptic drug (AED) for add-on treatment in adults with refractory partial seizures as shown in three pivotal controlled trials." | 6.38 | Felbamate: successful development of a new compound for the treatment of epilepsy. ( Schmidt, D, 1993) |
| "9%) seizure frequency was reduced by more than 50% (mean FBM dosage 3211 mg), and 13 patients (31." | 5.34 | [Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine, and sulthiame]. ( Bauer, J; Chahem, J, 2007) |
| "The patient experienced complete seizure control and almost complete return of language skills following the addition of felbamate." | 5.29 | Felbamate in the treatment of acquired epileptic aphasia. ( Glauser, TA; Olberding, LS; Piccirillo, DM; Titanic, MK, 1995) |
| "Pretreatment with felbamate at either dose prevented the progression of rank of seizures during chronic treatment with PTZ." | 5.29 | Anticonvulsant effect of felbamate in the pentylenetetrazole kindling model of epilepsy in the rat. ( Carboni, G; Corda, MG; Feldman, A; Frau, V; Giorgi, O; Orlandi, M; Valentini, V, 1996) |
| "We studied the efficacy of felbamate (FBM) in combination with valproic acid (VPA) in 13 patients with the Lennox-Gastaut syndrome and evaluated the contribution of each drug." | 5.09 | The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. ( Flamini, R; Gaillard, WD; Kelley, K; Ko, D; Malow, B; Reeves-Tyer, P; Siegel, H; Stertz, B; Theodore, WH, 1999) |
| "Felbamate is a novel anti-epileptic drug (AED) which has recently been associated with reports of aplastic anaemia and liver failure." | 5.08 | Felbamate as add-on therapy. ( Duncan, JS; Li, LM; Moriarty, J; Nashef, L; Sander, JW, 1996) |
| "The objective of this study was to assess the psychiatric effects of the antiepileptic drug (AED) felbamate (FBM) in patients with epilepsy." | 5.08 | Felbamate monotherapy has stimulant-like effects in patients with epilepsy. ( Flamini, R; Ketter, TA; Ko, D; Malow, BA; Post, RM; Theodore, WH; White, SR, 1996) |
| "Subjects with epilepsy (three men and seven women; age range, 20 to 39 years; weight range, 53 to 88 kg) who were previously stabilized with valproic acid, 9." | 5.07 | The effect of felbamate on valproic acid disposition. ( Graves, NM; Leppik, IE; Perhach, JL; Remmel, RP; Shumaker, RC; Wagner, ML; Ward, DL, 1994) |
| "Felbamate (FBM, Felbatol/Taloxa), a new antiepileptic drug (AED), was tested in a placebo-controlled add-on design in 73 patients with therapy refractory Lennox-Gastaut syndrome." | 5.07 | Felbamate in the treatment of Lennox-Gastaut syndrome. ( Jensen, PK, 1994) |
| " The USA guideline for epilepsy treatment recommends that patients with newly diagnosed epilepsy can be treated with gabapentin, lamotrigine, topiramate, and oxcarbazepine." | 4.84 | [Newer antiepileptic drugs]. ( Matsuura, M, 2007) |
| "Since 1993, eight new antiepileptic drugs (AEDs) have become available in the United States for the treatment of epilepsy: felbamate, gabapentin, lamotrigine, topiramate, tiagabine, levetiracetam, oxcarbazepine, and zonisamide." | 4.81 | Some common issues in the use of antiepileptic drugs. ( Asconapé, JJ, 2002) |
| "The introduction of these new antiepileptic drugs, from felbamate to levetiracetam, raised hope of control of epilepsy with fewer adverse effects and improved quality of life." | 4.81 | New antiepileptic drug therapies. ( Bergin, AM; Connolly, M, 2002) |
| " More specifically, vigabatrin, which is a very useful and well tolerated new antiepileptic drug for refractory partial epilepsy, should be started at a low dosage of 0." | 4.79 | The new anticonvulsant drugs. Implications for avoidance of adverse effects. ( Krämer, G; Schmidt, D, 1994) |
| "After the first year of clinical experience, felbamate (FBM) appears to be a valuable antiepileptic drug (AED) for the treatment of intractable epilepsy." | 4.79 | Felbamate. ( Leppik, IE, 1995) |
| "Since 1994, three new antiepileptic drugs, felbamate, lamotrigene, and gabapentin, have been released for the treatment of epilepsy." | 4.79 | A review of the newer antiepileptic drugs and the ketogenic diet. ( Barron, TF; Hunt, SL, 1997) |
| "This article provides an analysis of the degree of agreement between in vivo interaction studies performed in patients with epilepsy and healthy individuals, and in vitro studies which identified the cytochromes P450 (CYP) inhibited by felbamate and those involved in its metabolism." | 4.79 | Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation. ( Banfield, CR; Glue, P; Levy, RH; Mather, GG; Perhach, JL; Racha, JK, 1997) |
| " Felbamate (FBM) is effective in the treatment of partial seizures and Lennox-Gastaut epilepsy." | 4.78 | Advances in the pharmacotherapy of epilepsy. ( Ramsay, RE, 1993) |
| "This single center analysis retrospectively evaluated the safety and efficacy of felbamate in a cohort of children, adolescents, and adults with epilepsy." | 3.83 | Evaluating the safety and efficacy of felbamate in the context of a black box warning: A single center experience. ( Devinsky, O; Friedman, D; Kothare, SV; Shah, YD; Singh, K, 2016) |
| "Our patient's electrographic status epilepticus of sleep resolved after treatment with felbamate." | 3.81 | Successful Treatment of Electrographic Status Epilepticus of Sleep With Felbamate in a Patient With SLC9A6 Mutation. ( Coorg, R; Weisenberg, JL, 2015) |
| "To present our experience with felbamate therapy in children with drug-resistant epilepsy." | 3.80 | Efficacy and safety of felbamate in children with refractory epilepsy. ( Epstein, O; Gandelman-Marton, R; Heyman, E; Lahat, E; Levin, N, 2014) |
| "We present an implementation of a method we previously reported allowing the newer antiepileptic drugs (AEDs) rufinamide (RFN) and zonisamide (ZNS) to be simultaneously determined with lamotrigine (LTG), oxcarbazepine's (OXC) main active metabolite monohydroxycarbamazepine (MHD) and felbamate (FBM) in plasma of patients with epilepsy using high performance liquid chromatography (HPLC) with UV detection." | 3.76 | Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy. ( Albani, F; Baruzzi, A; Candela, C; Contin, M; Mohamed, S; Riva, R, 2010) |
| "The antiepileptic drug felbamate has demonstrated efficacy against a variety of seizure types in the pediatric population, particularly seizures associated with Lennox-Gastaut syndrome." | 3.76 | Efficacy of felbamate in the treatment of intractable pediatric epilepsy. ( Chico, MS; Eggener, KA; Hecox, KE; Marcuccilli, CJ; O'Connor, SE; Roell Werner, R; Schwabe, MS; Zupanc, ML, 2010) |
| "This article describes a simple isocratic high-performance liquid chromatographic (HPLC) method with UV detection for the determination of felbamate in the serum of patients with epilepsy." | 3.74 | Drug monitoring and toxicology: a simple procedure for the monitoring of felbamate by HPLC-UV detection. ( Tang, PH, 2008) |
| " By univariate analysis, those achieving seizure remission were probably much older, to have a shorter history of epilepsy and a lower frequency of seizures before felbamate therapy." | 3.74 | Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review. ( Balestri, P; Berardi, R; Coppola, G; Cordelli, DM; Franzoni, E; Grosso, S; Verrotti, A, 2008) |
| "A very simple and fast method has been developed and validated for simultaneous determination of the new generation antiepileptic drugs (AEDs) lamotrigine (LTG), oxcarbazepine's (OXC) main active metabolite monohydroxycarbamazepine and felbamate in plasma of patients with epilepsy using high-performance liquid chromatography (HPLC) with spectrophotometric detection." | 3.73 | Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. ( Albani, F; Balboni, M; Baruzzi, A; Callegati, E; Candela, C; Contin, M; Riva, R, 2005) |
| "The aim of the study was to assess the efficacy and safety of felbamate (FBM) as add-on therapy in pediatric patients with severe uncontrolled seizures during a 3-year follow-up." | 3.71 | The long-term use of felbamate in children with severe refractory epilepsy. ( Cilio, MR; Kartashov, AI; Vigevano, F, 2001) |
| "Influence Felbamate on the cerebral bioelectric activity (EEG) in the group of 31 children (18 with syndrome Lennox-Gastaut, 13 with partial epilepsy) with refractory epilepsy was investigated." | 3.70 | [Preliminary assessment of felbamate effect on the cerebral bioelectrical activity in children with refractory epilepsy]. ( Kuszczak, B; Mazur, J; Pakszys, M; Rusek, G; Szamotulska, K, 2000) |
| "The usefulness of felbamate (FBM) levels in managing epilepsy patients has not been determined." | 3.69 | Felbamate levels in patients with epilepsy. ( Harden, CL; Kutt, H; Trifiletti, R, 1996) |
| "We prospectively investigated drug-induced headaches (HA) among 60 epileptic patients receiving felbamate (FBM)." | 3.69 | Felbamate-induced headache. ( Andriola, MR; Berdia, A; Ettinger, AB; Jandorf, L; Krupp, LB; Weisbrot, DM, 1996) |
| "The behavioral effects of felbamate were assessed in 20 persons, (ages 2 to 19 years) who were participating in a compassionate plea protocol for children with Lennox-Gastaut syndrome." | 3.69 | Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). ( Coskey, JS; Gay, PE; Mecham, GF; Sadler, T; Thompson, JA, 1995) |
| "Felbamate was compared with several antiepileptic drugs for protective effects in two rat models of status epilepticus." | 3.68 | Effects of felbamate and other anticonvulsant drugs in two models of status epilepticus in the rat. ( Diamantis, W; Gels, M; Gordon, R; Sofia, RD, 1993) |
| "The phenytoin treatment causes cerebellar defect and anemia." | 2.82 | The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches. ( Agrawal, M; Dhurandhar, Y; Panda, SP, 2022) |
| "This open-label study investigated the pharmacokinetic interaction of phenytoin (PHT) and felbamate (FBM)." | 2.69 | Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate. ( Lyness, WH; Perhach, JL; Rosenberg, A; Sachdeo, R; Sachdeo, S; Shumaker, RC; Wagner, ML; Ward, D, 1999) |
| "Felbamate (FBM) pharmacokinetic parameters, safety and tolerability in the dose range of 1,200-6,000 mg/day were assessed in two open-label studies with similar designs." | 2.68 | Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy. ( Lyness, WH; Narang-Sachdeo, SK; Perhach, JL; Rosenberg, A; Sachdeo, R; Shumaker, RC, 1997) |
| "felbamate appears to be an effective new AED: the most adverse effects occurring during administration of FBM are mild to moderate gastrointestinal (nausea, vomiting and anorexia) and central nervous system (headache, sonnolence, diplopia, dizziness and insomnia) disturbances." | 2.68 | [Felbamate: a long-term study in subjects with refractory epilepsy]. ( De Romanis, F; Sopranzi, N, 1997) |
| "Felbamate is a novel antiepileptic drug that is now available in the United States." | 2.67 | Effect of felbamate on carbamazepine and its major metabolites. ( Graves, NM; Leppik, IE; Remmel, RP; Wagner, ML, 1993) |
| "Felbamate (FBM) is a new antiepileptic drug (AED) that has been evaluated in partial seizures and in the Lennox-Gastaut syndrome (LGS)." | 2.67 | Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. ( Dodson, WE, 1993) |
| " Consequently, the controlled trial was designed to account for this interaction by reducing the phenytoin dosage by approximately 20% during the felbamate treatment period and using matching placebo capsules to maintain the blind." | 2.67 | Dosage adjustments in response to monitored plasma concentrations: can unblinded staff adhere to objective criteria? ( Pledger, GW; Sahlroot, JT, 1994) |
| "Safety and efficacy studies of new antiepileptic drugs require strict adherence to prescribed dosage regimens." | 2.66 | Compliant populations: variability in serum concentrations. ( Graves, NM; Holmes, GB; Leppik, IE, 1988) |
| " For drugs that are eliminated renally completely unchanged (gabapentin, pregabalin and vigabatrin) or mainly unchanged (levetiracetam and topiramate), the pharmacokinetic variability is less pronounced and more predictable." | 2.43 | Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? ( Johannessen, SI; Tomson, T, 2006) |
| "Felbamate has demonstrated efficacy against a variety of refractory seizures types, including seizures associated with Lennox-Gastaut syndrome, but postmarketing experience revealed serious idiosyncratic adverse effects that were not observed during clinical trials." | 2.43 | Felbamate: consensus of current clinical experience. ( Faught, E; Leppik, IE; Pellock, JM; Shinnar, S; Zupanc, ML, 2006) |
| "The pharmacokinetic properties of a drug are the primary deter-minant of the extent and duration of drug action, and influence susceptibility to clinically important drug interactions." | 2.42 | The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ( Johannessen, SI; Perucca, E, 2003) |
| " So the search for more effective drugs with minimal adverse effect profiles will continue." | 2.42 | Adverse effects of new antiepileptic drugs. ( Onat, F; Ozkara, C, 2004) |
| "Although antiepileptic drugs (AEDs) are commonly used to control and prevent seizures, their long-term use carries a considerable risk of morbidity." | 2.41 | Antiepileptic drug therapy for adults: when to initiate and how to choose. ( Sirven, JI, 2002) |
| "Epilepsy affects 1." | 2.41 | New antiepileptic drugs and preparations. ( Jagoda, A; Yoon, Y, 2000) |
| "Felbamate, however, has been linked with substantially increased incidence of aplastic anemia, and the other new AEDs have been studied for relatively short periods of time." | 2.40 | Pharmacologic and dietary therapies in epilepsy: conventional treatments and recent advances. ( Chapman, DP; Giles, WH, 1997) |
| "Felbamate (FBM) is a new antiepileptic drug (AED) that is often effective in seizure disorders refractory to other treatments; its use has been greatly restricted after cases of aplastic anemia were reported." | 2.40 | Evaluation of case reports of aplastic anemia among patients treated with felbamate. ( Anderson, T; Harmon, DC; Kaufman, DW; Kelly, JP; Shapiro, S, 1997) |
| "To most effectively treat children with epilepsy syndromes, further research must be completed to validate the positive effects described in case reports, open-label clinical trials, and early controlled clinical trials." | 2.40 | Managing pediatric epilepsy syndromes with new antiepileptic drugs. ( Pellock, JM, 1999) |
| "Successful treatment of seizure disorders in small animals requires proper patient assessment, understanding the principles of antiepileptic drug (AED) therapy, designing a strategy for pharmacotherapy, and plans for emergency treatment." | 2.40 | Antiepileptic drug therapy. ( Podell, M, 1998) |
| "Felbamate was launched in 1993 in the U." | 2.40 | Felbamate: clinical and molecular aspects of a unique antiepileptic drug. ( Aiken, SP; Brown, WM, 1998) |
| "Felbamate (FBM) was the first of the new antiepileptic drugs (AEDs) approved in the United States in 1993 with broad-spectrum efficacy against partial and generalized seizures of various types, and indicated for use as adjunctive and monotherapy." | 2.40 | Felbamate. ( Pellock, JM, 1999) |
| " For all drugs that are metabolized, half-life is shortened and clearance is increased when patients receive concomitant enzyme-inducing agents such as barbiturates, phenytoin, and carbamazepine." | 2.40 | The clinical pharmacokinetics of the new antiepileptic drugs. ( Perucca, E, 1999) |
| "Felbamate was submitted to innovative and unconventional clinical trials." | 2.40 | Felbamate. ( Bourgeois, BF, 1997) |
| "Standard antiepileptic drugs (AEDs) are associated with a wide variety of acute and chronic adverse events and with many interactions with each other and with non-AEDs that complicate patient management." | 2.40 | Overview of the safety of newer antiepileptic drugs. ( Shorvon, S; Stefan, H, 1997) |
| "Antiepileptic drugs (AEDs) in broad use today have a number of pharmacokinetic liabilities, including a propensity for clinically meaningful drug interactions." | 2.39 | Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. ( Perucca, E, 1996) |
| "Felbamate was licensed in 1993 for use as adjunctive therapy or monotherapy in adults with partial or tonic-clonic seizures and as adjunctive therapy for children with the Lennox-Gastaut syndrome." | 2.39 | Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin. ( Laxer, KD, 1994) |
| "Felbamate is a new anticonvulsant which has already been marketed in some countries outside Germany, i." | 2.39 | [The pharmacologic and clinical profile of the new anticonvulsant felbamate--an overview]. ( Steinhoff, BJ, 1994) |
| "For many years, the medical treatment of epilepsy was based on the use of the same few drugs, which were chosen according to the seizure type in a fairly standardized manner." | 2.39 | New antiepileptic drugs. ( Bourgeois, BF, 1996) |
| " Specific indications and dosage schedules have been provided." | 2.39 | New antiepileptic drugs. ( Brodie, MJ; Wilson, EA, 1996) |
| "Epilepsy is one of the most common neurological disorders." | 2.39 | Newer antiepileptic drugs. Towards an improved risk-benefit ratio. ( Patsalos, PN; Sander, JW, 1994) |
| "This article surveys the pharmacokinetic parameters for the new antiepileptic drugs (AEDs): felbamate, gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, and vigabatrin." | 2.39 | Pharmacokinetics of new antiepileptic drugs. ( Gram, L, 1996) |
| "Felbamate has been used effectively as monotherapy and adjunctive therapy in patients with partial seizures with or without secondary generalization and as adjunctive therapy in children with partial or generalized seizures associated with Lennox-Gastaut syndrome." | 2.39 | Felbamate: a new antiepileptic drug. ( Wagner, ML, 1994) |
| " ZNS daily dosage is 400-600 mg." | 2.39 | Antiepileptic drugs in development: prospects for the near future. ( Leppik, IE, 1994) |
| "Epilepsy is common in individuals who are mentally retarded and/or otherwise multiply handicapped." | 2.39 | The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps. ( Mattson, RH, 1996) |
| " Clinical evaluation of AEDs is both difficult and complex, due mainly to two factors: (1) intermittence of clinical events, which means that dosing for periods of several weeks is generally necessary, leading to problems of poor compliance and inaccurate reporting of events by carers and patients; and (2) therapeutic necessity, which means that it is, in general, unacceptable to withhold effective treatment from a person with epilepsy." | 2.39 | Design of clinical antiepileptic drug trials. ( Binnie, CD, 1995) |
| "Epilepsy is a disorder of the central nervous system in which the clinical symptoms are recurrent seizures." | 2.38 | Advances in pharmacotherapy: recent developments in the treatment of epilepsy. ( Graves, NM; Leppik, IE, 1993) |
| "Felbamate (FBM) is an effective and safe novel antiepileptic drug (AED) for add-on treatment in adults with refractory partial seizures as shown in three pivotal controlled trials." | 2.38 | Felbamate: successful development of a new compound for the treatment of epilepsy. ( Schmidt, D, 1993) |
| "9%) seizure frequency was reduced by more than 50% (mean FBM dosage 3211 mg), and 13 patients (31." | 1.34 | [Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine, and sulthiame]. ( Bauer, J; Chahem, J, 2007) |
| "Felbamate is an antiepileptic drug that is associated with minimal toxicity in preclinical species such as rat and dog but has an unacceptable incidence of serious idiosyncratic reactions in man." | 1.34 | Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression. ( Johnson, MD; Kao, LM; Kelley, MF; Leone, AM; Lord, PG; McMillian, MK; Nie, AY; Parker, JB; Parkinson, A; Usuki, E, 2007) |
| " LEV and FBM brain concentrations were measured by HPLC in order to determine any pharmacokinetic contribution to the observed antiseizure effect." | 1.34 | Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model. ( Andres-Mach, MM; Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2007) |
| "The lamotrigine level was 14." | 1.33 | Lamotrigine as a possible cause of QRS prolongation in a patient with known seizure disorder. ( Herold, TJ, 2006) |
| "Felbamate therapy was consider to be the turning-point in both therapeutic and diagnostic meaning." | 1.31 | [Positive effect of falbamate therapy in a boy with refractory epilepsy]. ( Pakszys, M; Rusek, G; Szczepanik, E, 2000) |
| "Felbamate (FBM) was initiated and VPA discontinued for improved seizure control." | 1.30 | Male infertility: possible association with valproate exposure. ( McCoy, GB; Yerby, MS, 1999) |
| "Pretreatment with felbamate at either dose prevented the progression of rank of seizures during chronic treatment with PTZ." | 1.29 | Anticonvulsant effect of felbamate in the pentylenetetrazole kindling model of epilepsy in the rat. ( Carboni, G; Corda, MG; Feldman, A; Frau, V; Giorgi, O; Orlandi, M; Valentini, V, 1996) |
| "The patient experienced complete seizure control and almost complete return of language skills following the addition of felbamate." | 1.29 | Felbamate in the treatment of acquired epileptic aphasia. ( Glauser, TA; Olberding, LS; Piccirillo, DM; Titanic, MK, 1995) |
| "Felbamate is a new antiepileptic drug (AED) with a good safety profile." | 1.29 | Weight loss in patients taking felbamate. ( Bergen, DC; Hoeppner, TJ; Kanner, A; Ristanovic, RK; Waicosky, K, 1995) |
Research
Studies (142)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.41) | 18.7374 |
| 1990's | 95 (66.90) | 18.2507 |
| 2000's | 35 (24.65) | 29.6817 |
| 2010's | 7 (4.93) | 24.3611 |
| 2020's | 3 (2.11) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Panda, SP | 1 |
| Dhurandhar, Y | 1 |
| Agrawal, M | 1 |
| Tomson, T | 2 |
| Battino, D | 1 |
| Bromley, R | 1 |
| Kochen, S | 1 |
| Meador, KJ | 1 |
| Pennell, PB | 1 |
| Thomas, SV | 1 |
| Hussain, SA | 1 |
| Asilnejad, B | 1 |
| Heesch, J | 1 |
| Navarro, M | 1 |
| Ji, M | 1 |
| Shrey, DW | 1 |
| Rajaraman, RR | 1 |
| Sankar, R | 1 |
| Heyman, E | 1 |
| Levin, N | 1 |
| Lahat, E | 1 |
| Epstein, O | 1 |
| Gandelman-Marton, R | 1 |
| Coorg, R | 1 |
| Weisenberg, JL | 1 |
| Shah, YD | 1 |
| Singh, K | 1 |
| Friedman, D | 1 |
| Devinsky, O | 2 |
| Kothare, SV | 1 |
| Tang, PH | 1 |
| Grosso, S | 1 |
| Cordelli, DM | 1 |
| Coppola, G | 1 |
| Franzoni, E | 1 |
| Verrotti, A | 1 |
| Berardi, R | 1 |
| Balestri, P | 1 |
| Hill, AJ | 1 |
| Jones, NA | 1 |
| Williams, CM | 1 |
| Stephens, GJ | 1 |
| Whalley, BJ | 1 |
| Contin, M | 2 |
| Mohamed, S | 1 |
| Candela, C | 2 |
| Albani, F | 2 |
| Riva, R | 2 |
| Baruzzi, A | 2 |
| Cavanna, AE | 1 |
| Ali, F | 1 |
| Rickards, HE | 1 |
| McCorry, D | 1 |
| Zupanc, ML | 2 |
| Roell Werner, R | 1 |
| Schwabe, MS | 1 |
| O'Connor, SE | 1 |
| Marcuccilli, CJ | 1 |
| Hecox, KE | 1 |
| Chico, MS | 1 |
| Eggener, KA | 1 |
| Potschka, H | 2 |
| Fedrowitz, M | 2 |
| Löscher, W | 2 |
| Asconapé, JJ | 1 |
| Héberlé, C | 1 |
| Berquin, P | 1 |
| Larnicol, N | 1 |
| Wallois, F | 1 |
| Sirven, JI | 1 |
| Bergin, AM | 1 |
| Connolly, M | 1 |
| Perucca, E | 3 |
| Johannessen, SI | 2 |
| Onat, F | 1 |
| Ozkara, C | 1 |
| Luszczki, JJ | 2 |
| Czuczwar, SJ | 2 |
| Harrison, PK | 1 |
| Sheridan, RD | 1 |
| Green, AC | 1 |
| Tattersall, JE | 1 |
| Balboni, M | 1 |
| Callegati, E | 1 |
| Pellock, JM | 8 |
| Faught, E | 2 |
| Leppik, IE | 8 |
| Shinnar, S | 1 |
| Roecklein, BA | 1 |
| Sacks, HJ | 1 |
| Mortko, H | 1 |
| Stables, J | 1 |
| Andres-Mach, MM | 1 |
| Ratnaraj, N | 1 |
| Patsalos, PN | 2 |
| Matsuura, M | 1 |
| Herold, TJ | 1 |
| Leone, AM | 1 |
| Kao, LM | 1 |
| McMillian, MK | 1 |
| Nie, AY | 1 |
| Parker, JB | 1 |
| Kelley, MF | 1 |
| Usuki, E | 1 |
| Parkinson, A | 1 |
| Lord, PG | 1 |
| Johnson, MD | 1 |
| Chahem, J | 1 |
| Bauer, J | 1 |
| Dannhardt, G | 1 |
| Kiefer, W | 1 |
| Hwang, H | 1 |
| Kim, KJ | 1 |
| Macdonald, RL | 1 |
| Kelly, KM | 1 |
| Binnie, CD | 1 |
| Theodore, WH | 4 |
| Albert, P | 1 |
| Stertz, B | 2 |
| Malow, B | 2 |
| Ko, D | 3 |
| White, S | 1 |
| Flamini, R | 3 |
| Ketter, T | 1 |
| Kupecz, D | 1 |
| Palmer, KJ | 1 |
| McTavish, D | 1 |
| Glauser, TA | 2 |
| Olberding, LS | 1 |
| Titanic, MK | 1 |
| Piccirillo, DM | 1 |
| Schmidt, D | 2 |
| Krämer, G | 1 |
| Herranz, JL | 2 |
| Arteaga, R | 1 |
| Armijo, JA | 1 |
| Vazquez, B | 1 |
| Luciano, D | 1 |
| Sander, JW | 2 |
| Grossmann, R | 1 |
| Maytal, J | 1 |
| Fernando, J | 1 |
| Wagner, ML | 4 |
| Luer, MS | 1 |
| Buchanan, N | 1 |
| Graves, NM | 4 |
| Remmel, RP | 2 |
| Shumaker, RC | 4 |
| Ward, DL | 1 |
| Perhach, JL | 7 |
| Laxer, KD | 1 |
| Steinhoff, BJ | 1 |
| Sahlroot, JT | 2 |
| Pledger, GW | 2 |
| Jensen, PK | 1 |
| Parks, BR | 1 |
| Dostrow, VG | 1 |
| Noble, SL | 1 |
| Byers, VL | 1 |
| Skolnick, AA | 1 |
| Manack, L | 1 |
| Dodson, WE | 1 |
| Ramsay, RE | 2 |
| Slater, JD | 1 |
| Shields, WD | 1 |
| Herranz Fernández, JL | 1 |
| Nightingale, SL | 1 |
| Heinzl, S | 1 |
| Sofia, RD | 4 |
| Gordon, R | 1 |
| Gels, M | 1 |
| Diamantis, W | 1 |
| Lee, EK | 1 |
| Harden, CL | 1 |
| Trifiletti, R | 1 |
| Kutt, H | 1 |
| Ettinger, AB | 1 |
| Jandorf, L | 1 |
| Berdia, A | 1 |
| Andriola, MR | 1 |
| Krupp, LB | 1 |
| Weisbrot, DM | 1 |
| Gay, PE | 1 |
| Mecham, GF | 1 |
| Coskey, JS | 1 |
| Sadler, T | 1 |
| Thompson, JA | 1 |
| Legido, A | 1 |
| Bergen, DC | 1 |
| Ristanovic, RK | 1 |
| Waicosky, K | 1 |
| Kanner, A | 1 |
| Hoeppner, TJ | 1 |
| Iivanainen, M | 1 |
| Gaily, E | 1 |
| Li, LM | 1 |
| Nashef, L | 1 |
| Moriarty, J | 1 |
| Duncan, JS | 1 |
| Giorgi, O | 1 |
| Carboni, G | 1 |
| Frau, V | 1 |
| Orlandi, M | 1 |
| Valentini, V | 1 |
| Feldman, A | 1 |
| Corda, MG | 1 |
| Hussein, G | 1 |
| Troupin, AS | 1 |
| Montouris, G | 2 |
| Gram, L | 1 |
| Meldrum, BS | 1 |
| Mattson, RH | 1 |
| Avanzini, G | 1 |
| Canger, R | 1 |
| Dalla Bernardina, B | 1 |
| Vigevano, F | 2 |
| Ketter, TA | 2 |
| Malow, BA | 2 |
| White, SR | 1 |
| Post, RM | 2 |
| Grippo, J | 1 |
| Appleton, RE | 1 |
| Bourgeois, BF | 3 |
| Morris, HH | 1 |
| Wilson, EA | 1 |
| Brodie, MJ | 2 |
| Shorvon, S | 1 |
| Stefan, H | 1 |
| Padró, L | 1 |
| Arbizu, T | 1 |
| Rovira, R | 1 |
| Chapman, DP | 1 |
| Giles, WH | 1 |
| Wyler, AR | 1 |
| Vossler, DG | 1 |
| Barron, TF | 1 |
| Hunt, SL | 1 |
| Glue, P | 1 |
| Banfield, CR | 1 |
| Mather, GG | 1 |
| Racha, JK | 1 |
| Levy, RH | 1 |
| Burdette, DE | 1 |
| Sackellares, JC | 1 |
| De Romanis, F | 1 |
| Sopranzi, N | 1 |
| Sunder, TR | 1 |
| Bazil, CW | 1 |
| Pedley, TA | 1 |
| Sachdeo, RC | 1 |
| Narang-Sachdeo, S | 1 |
| Montgomery, PA | 1 |
| Lyness, WH | 3 |
| Rosenberg, A | 4 |
| Kaufman, DW | 1 |
| Kelly, JP | 1 |
| Anderson, T | 1 |
| Harmon, DC | 1 |
| Shapiro, S | 1 |
| Sachdeo, R | 2 |
| Narang-Sachdeo, SK | 1 |
| Stefani, A | 1 |
| Spadoni, F | 1 |
| Bernardi, G | 1 |
| De Sarro, GB | 1 |
| Berlinghieri, MC | 1 |
| Elia, M | 1 |
| Musumeci, SA | 1 |
| David, E | 1 |
| Dominijanni, A | 1 |
| Gulletta, E | 1 |
| Podell, M | 1 |
| Marciani, MG | 1 |
| Spanedda, F | 1 |
| Placidi, F | 1 |
| Bassetti, MA | 1 |
| Romigi, A | 1 |
| Mattia, D | 1 |
| Brown, WM | 1 |
| Aiken, SP | 1 |
| Wilner, AN | 1 |
| Siegel, H | 1 |
| Kelley, K | 1 |
| Reeves-Tyer, P | 1 |
| Gaillard, WD | 1 |
| Yerby, MS | 1 |
| McCoy, GB | 1 |
| French, J | 1 |
| Smith, M | 1 |
| Brown, L | 1 |
| Thompson, CD | 2 |
| Barthen, MT | 2 |
| Hopper, DW | 1 |
| Miller, TA | 2 |
| Quigg, M | 1 |
| Hudspeth, C | 1 |
| Marsh, L | 1 |
| Macdonald, TL | 2 |
| Sachdeo, S | 1 |
| Ward, D | 1 |
| Appleton, R | 1 |
| Benbadis, S | 1 |
| Dieckhaus, CM | 1 |
| Szczepanik, E | 1 |
| Pakszys, M | 2 |
| Rusek, G | 2 |
| Kuszczak, B | 1 |
| Szamotulska, K | 1 |
| Mazur, J | 1 |
| Vajda, FJ | 1 |
| Rogawski, MA | 1 |
| Wasterlain, CG | 1 |
| Mazarati, AM | 1 |
| Foletti, GB | 1 |
| Yoon, Y | 1 |
| Jagoda, A | 1 |
| Sparagana, SP | 1 |
| Strand, WR | 1 |
| Adams, RC | 1 |
| French, JA | 1 |
| Cilio, MR | 1 |
| Kartashov, AI | 1 |
| Kramer, L | 1 |
| Porter, RJ | 1 |
| Holmes, GB | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Normalization of Sodium on Bone Markers in Patients With Epilepsy. A Randomized Single-blinded Placebo-controlled Trial.[NCT03371199] | 21 participants (Actual) | Interventional | 2017-12-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
73 reviews available for felbamate and Aura
| Article | Year |
|---|---|
The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches.
Topics: Anticonvulsants; Carbamazepine; Dementia; Epilepsy; Felbamate; Gabapentin; Humans; Inflammasomes; La | 2022 |
Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force
Topics: Breast Feeding; Cannabidiol; Carbamazepine; Child; Clobazam; Clonazepam; Epilepsy; Ethosuximide; Eve | 2022 |
Behavioral and cognitive effects of anti-epileptic drugs.
Topics: Amines; Anticonvulsants; Antidepressive Agents; Behavior; Cognition; Cognition Disorders; Cyclohexan | 2010 |
Some common issues in the use of antiepileptic drugs.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Anticonvulsants; Body Weight; Cognition Disorders; Drug E | 2002 |
Antiepileptic drug therapy for adults: when to initiate and how to choose.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Felb | 2002 |
New antiepileptic drug therapies.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Ep | 2002 |
The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interac | 2003 |
Adverse effects of new antiepileptic drugs.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Epilepsy; Felbamate; Humans; Phenylcarbamat | 2004 |
Felbamate: consensus of current clinical experience.
Topics: Anticonvulsants; Drug Interactions; Drug Therapy, Combination; Epilepsy; Felbamate; Humans; Language | 2006 |
Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interactions; Drug Monitor | 2006 |
Fluorofelbamate.
Topics: Animals; Anticonvulsants; Brain; Clinical Trials as Topic; Epilepsy; Felbamate; Humans; Phenylcarbam | 2007 |
[Newer antiepileptic drugs].
Topics: Amines; Animals; Anti-Anxiety Agents; Anticonvulsants; Calcium Channel Blockers; Carbamazepine; Cycl | 2007 |
[New antiepileptics in development].
Topics: Animals; Anticonvulsants; Benzodiazepines; Carbamazepine; Epilepsy; Felbamate; Humans; Levetiracetam | 2007 |
Mechanisms of action of currently prescribed and newly developed antiepileptic drugs.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Drugs, Investigational; Epi | 1994 |
Design of clinical antiepileptic drug trials.
Topics: Anticonvulsants; Bias; Clinical Trials, Phase II as Topic; Controlled Clinical Trials as Topic; Drug | 1995 |
Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy.
Topics: Adolescent; Adult; Animals; Anticonvulsants; Child; Child, Preschool; Drug Interactions; Epilepsy; F | 1993 |
The new anticonvulsant drugs. Implications for avoidance of adverse effects.
Topics: Abnormalities, Drug-Induced; Anemia, Aplastic; Anticonvulsants; Chemical and Drug Induced Liver Inju | 1994 |
[New antiepileptic drugs: vagabatrin, lamotrigine and felbamate].
Topics: Anticonvulsants; Epilepsy; Felbamate; gamma-Aminobutyric Acid; Humans; Lamotrigine; Phenylcarbamates | 1994 |
New antiepileptic drugs for children: felbamate, gabapentin, lamotrigine, and vigabatrin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Approval; Epileps | 1994 |
Newer antiepileptic drugs. Towards an improved risk-benefit ratio.
Topics: Acetamides; Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dioxolane | 1994 |
Felbamate: a new antiepileptic drug.
Topics: Anticonvulsants; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Drug Interactions; | 1994 |
New anti-epileptic drugs in the 1990s.
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam | 1994 |
Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin.
Topics: Acetates; Adult; Amines; Animals; Anticonvulsants; Child; Clinical Protocols; Controlled Clinical Tr | 1994 |
[The pharmacologic and clinical profile of the new anticonvulsant felbamate--an overview].
Topics: Adult; Anticonvulsants; Child; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epilepsy | 1994 |
Drug therapy for epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Decision Trees; Epilepsy; Felbamate; | 1994 |
Antiepileptic drugs in development: prospects for the near future.
Topics: Acetates; Adult; Amines; Aminocaproates; Animals; Anticonvulsants; Clinical Trials as Topic; Cyclohe | 1994 |
Advances in pharmacotherapy: recent developments in the treatment of epilepsy.
Topics: Acetates; Amines; Aminocaproates; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Aci | 1993 |
Felbamate: successful development of a new compound for the treatment of epilepsy.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, | 1993 |
Antiepileptic drugs in clinical development.
Topics: Acetates; Amines; Aminocaproates; Anticonvulsants; Brain; Clinical Trials as Topic; Cyclohexanecarbo | 1993 |
Investigational antiepileptic drugs for the treatment of childhood seizure disorders: a review of efficacy and safety.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Clinical Trials as | 1994 |
[Contribution of new drugs to the better control of epilepsy].
Topics: Aminocaproates; Anticonvulsants; Child; Delayed-Action Preparations; Epilepsy; Felbamate; Humans; Ph | 1993 |
Advances in the pharmacotherapy of epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Gabapentin; gam | 1993 |
Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Carbamazepine; Clinical Trials as Topic; | 1996 |
Utilization of new antiepileptic drugs in children.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Anticonvulsants; Carbamazepine; Child; Child, Pres | 1996 |
[Advances in the diagnostic and treatment of infantile epilepsy].
Topics: Acetates; Amines; Anticonvulsants; Brain; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Elec | 1996 |
[Current anti-epilepsy drugs].
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Therapy, Combina | 1995 |
Felbamate.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Interact | 1995 |
Pharmacokinetics of new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Carbamazepine; Cyclohexanecarboxylic Aci | 1996 |
Update on the mechanism of action of antiepileptic drugs.
Topics: 4-Aminobutyrate Transaminase; Acetamides; Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecar | 1996 |
The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps.
Topics: Acetates; Amines; Anticonvulsants; Cerebral Palsy; Cyclohexanecarboxylic Acids; Disabled Persons; Dr | 1996 |
[Advantages and disadvantages of new antiepileptic drugs].
Topics: Acetates; Adrenocorticotropic Hormone; Amines; Anticonvulsants; Brain; Cyclohexanecarboxylic Acids; | 1996 |
[Treatment of the epilepsy: new drugs].
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamaz | 1996 |
The new antiepileptic drugs.
Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Amines; Anticonvulsants; Child; Child, Pre | 1996 |
New antiepileptic drugs.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; F | 1996 |
New antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; | 1996 |
Overview of the safety of newer antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drug Inter | 1997 |
Felbamate.
Topics: Anticonvulsants; Child; Epilepsy; Felbamate; Humans; Phenylcarbamates; Propylene Glycols | 1997 |
[New antiepileptic drugs].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Gabapentin; gam | 1997 |
Pharmacologic and dietary therapies in epilepsy: conventional treatments and recent advances.
Topics: Acetates; Amines; Anticonvulsants; Benzodiazepines; Carbamazepine; Cyclohexanecarboxylic Acids; Epil | 1997 |
Recent advancements in epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose; Gabap | 1997 |
A review of the newer antiepileptic drugs and the ketogenic diet.
Topics: Acetates; Age Factors; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids | 1997 |
Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.
Topics: Anticonvulsants; Area Under Curve; Carbamazepine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-4 | 1997 |
Felbamate pharmacology and use in epilepsy.
Topics: Animals; Anticonvulsants; Epilepsy; Felbamate; Humans; Phenylcarbamates; Propylene Glycols | 1994 |
Meeting the challenge of epilepsy in persons with multiple handicaps.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Comorbidity; Developmental Disabilities | 1997 |
Overview of lamotrigine and the new antiepileptic drugs: the challenge.
Topics: Acetates; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Interactions; Epilepsy; | 1997 |
Advances in the medical treatment of epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Diazepam; Drug Approv | 1998 |
Evaluation of case reports of aplastic anemia among patients treated with felbamate.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Anemia, Aplastic; Anticonvulsants; Causality; Confou | 1997 |
Voltage-activated calcium channels: targets of antiepileptic drug therapy?
Topics: Animals; Anticonvulsants; Calcium Channels; Carbamazepine; Drug Design; Epilepsy; Felbamate; Humans; | 1997 |
Role of new and established antiepileptic drugs.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Drug Interactions; Epilepsies, Partial; Epilepsy | 1998 |
New antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Approval; Epilep | 1998 |
Antiepileptic drug therapy.
Topics: Acetates; Amines; Animals; Anticonvulsants; Bromides; Cat Diseases; Cats; Cyclohexanecarboxylic Acid | 1998 |
Felbamate: clinical and molecular aspects of a unique antiepileptic drug.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Drug Resistance; Epilepsy; Felbamate; Humans; In | 1998 |
New medication options for patients with epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose; Gabap | 1998 |
Felbamate in epilepsy therapy: evaluating the risks.
Topics: Animals; Anticonvulsants; Epilepsy; Felbamate; Female; Humans; Male; Phenylcarbamates; Propylene Gly | 1999 |
Use of new antiepileptic drugs in the treatment of childhood epilepsy.
Topics: Acetates; Adult; Age Factors; Amines; Anticonvulsants; Child; Clinical Trials as Topic; Cyclohexanec | 1999 |
Felbamate.
Topics: Adult; Age Factors; Anemia, Aplastic; Anorexia; Anticonvulsants; Child; Drug Administration Schedule | 1999 |
Managing pediatric epilepsy syndromes with new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose | 1999 |
The clinical pharmacokinetics of the new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Cyclohexanecarboxylic Acids; Dose-Respon | 1999 |
New antiepileptic drugs.
Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interac | 2000 |
Idiosyncratic reactions: new methods of identifying high-risk patients.
Topics: Anticonvulsants; Biomarkers; Drug Monitoring; Epilepsy; Epoxide Hydrolases; Felbamate; Free Radical | 2000 |
New antiepileptic drugs and preparations.
Topics: Acetates; Administration, Rectal; Age Factors; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; | 2000 |
The role of new antiepileptic drugs.
Topics: Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Epilepsies, Partial; Epilepsy; Epi | 2001 |
Felbamate.
Topics: Administration, Oral; Animals; Anticonvulsants; Dose-Response Relationship, Drug; Drugs, Investigati | 1991 |
Trials
16 trials available for felbamate and Aura
| Article | Year |
|---|---|
Felbamate monotherapy: implications for antiepileptic drug development.
Topics: Adolescent; Adult; Anticonvulsants; Double-Blind Method; Drug Administration Schedule; Drugs, Invest | 1995 |
The effect of felbamate on valproic acid disposition.
Topics: Adult; Cross-Over Studies; Drug Therapy, Combination; Epilepsy; Felbamate; Female; Humans; Male; Phe | 1994 |
Dosage adjustments in response to monitored plasma concentrations: can unblinded staff adhere to objective criteria?
Topics: Attitude of Health Personnel; Carbamazepine; Dose-Response Relationship, Drug; Double-Blind Method; | 1994 |
Felbamate in the treatment of Lennox-Gastaut syndrome.
Topics: Adult; Anticonvulsants; Child; Drugs, Investigational; Epilepsies, Partial; Epilepsy; Felbamate; Fol | 1994 |
Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial.
Topics: Anticonvulsants; Child; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalograph | 1993 |
Effect of felbamate on carbamazepine and its major metabolites.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Interactions; Epilepsy; | 1993 |
Felbamate as add-on therapy.
Topics: Adult; Anemia, Aplastic; Anticonvulsants; Epilepsy; Felbamate; Follow-Up Studies; Humans; Liver Fail | 1996 |
Felbamate in therapy-resistant epilepsy: an Italian experience. Felbamate Italian Study Group.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Anticonvulsants; Child; Child, Preschool; Drug Resistance | 1996 |
Felbamate monotherapy has stimulant-like effects in patients with epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy; Felbamate; Female; Humans; Male; Phenylcarbamates; Propylene Glyco | 1996 |
[Felbamate: a long-term study in subjects with refractory epilepsy].
Topics: Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsies, Partial; Epilepsy; | 1997 |
Evaluation of the potential interaction between felbamate and erythromycin in patients with epilepsy.
Topics: Adult; Anti-Bacterial Agents; Anticonvulsants; Cross-Over Studies; Drug Interactions; Epilepsy; Eryt | 1998 |
Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy.
Topics: Adolescent; Adult; Anorexia; Anticonvulsants; Area Under Curve; Dose-Response Relationship, Drug; Dr | 1997 |
The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cross-Over Studies; Double-Blind Method; Drug | 1999 |
Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interac | 1999 |
The synthesis, in vitro reactivity, and evidence for formation in humans of 5-phenyl-1,3-oxazinane-2,4-dione, a metabolite of felbamate.
Topics: Anticonvulsants; Biotransformation; Chromatography, High Pressure Liquid; Epilepsy; Felbamate; Human | 2000 |
Compliant populations: variability in serum concentrations.
Topics: Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combina | 1988 |
Other Studies
53 other studies available for felbamate and Aura
| Article | Year |
|---|---|
Felbamate in the treatment of refractory epileptic spasms.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Felbamate; Female; Humans; Infant; M | 2020 |
Efficacy and safety of felbamate in children with refractory epilepsy.
Topics: Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy; Felbamate; Female; Human | 2014 |
Successful Treatment of Electrographic Status Epilepticus of Sleep With Felbamate in a Patient With SLC9A6 Mutation.
Topics: Anticonvulsants; Ataxia; Child; Epilepsy; Felbamate; Genetic Diseases, X-Linked; Humans; Intellectua | 2015 |
Evaluating the safety and efficacy of felbamate in the context of a black box warning: A single center experience.
Topics: Adolescent; Adult; Age of Onset; Anemia, Aplastic; Anticonvulsants; Child; Cohort Studies; Drug Labe | 2016 |
Drug monitoring and toxicology: a simple procedure for the monitoring of felbamate by HPLC-UV detection.
Topics: Anticonvulsants; Chromatography, High Pressure Liquid; Drug Monitoring; Epilepsy; Felbamate; Humans; | 2008 |
Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review.
Topics: Anorexia; Anticonvulsants; Child, Preschool; Drug Evaluation; Drug Resistance; Epilepsy; Felbamate; | 2008 |
Development of multi-electrode array screening for anticonvulsants in acute rat brain slices.
Topics: 4-Aminopyridine; Animals; Animals, Newborn; Anticonvulsants; Disease Models, Animal; Drug Evaluation | 2010 |
Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy.
Topics: Anticonvulsants; Carbamazepine; Chromatography, High Pressure Liquid; Epilepsy; Felbamate; Humans; I | 2010 |
Efficacy of felbamate in the treatment of intractable pediatric epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy; Felbamate; F | 2010 |
P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barri | 2002 |
Vagus nerve stimulation in a case of epilepsy with CSWSS: respiratory side effects during sleep.
Topics: Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Clobazam; Combined Modali | 2002 |
Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats.
Topics: Amygdala; Animals; Anticonvulsants; Biological Availability; Blood-Brain Barrier; Carbamazepine; Cer | 2003 |
Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Drug Evaluation, Preclinical; Drug | 2004 |
Effects of anticonvulsants on soman-induced epileptiform activity in the guinea-pig in vitro hippocampus.
Topics: Amines; Animals; Anticonvulsants; Carbamates; Carbamazepine; Chlormethiazole; Clozapine; Cyclohexane | 2005 |
Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy.
Topics: Anticonvulsants; Carbamazepine; Chromatography, High Pressure Liquid; Dibenzazepines; Drug Monitorin | 2005 |
Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model.
Topics: Animals; Anticonvulsants; Behavior, Animal; Brain; Chromatography, High Pressure Liquid; Disease Mod | 2007 |
Lamotrigine as a possible cause of QRS prolongation in a patient with known seizure disorder.
Topics: Adult; Anticonvulsants; Electrocardiography; Epilepsy; Felbamate; Female; Humans; Lamotrigine; Pheny | 2006 |
Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression.
Topics: Animals; Anticonvulsants; Cells, Cultured; Epilepsy; Felbamate; Gene Expression Regulation; Humans; | 2007 |
[Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine, and sulthiame].
Topics: Adult; Anticonvulsants; Epilepsy; Felbamate; Humans; Nipecotic Acids; Phenylcarbamates; Propylene Gl | 2007 |
New antiepileptic drugs in pediatric epilepsy.
Topics: Amines; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Epilep | 2008 |
New drugs for the treatment of epilepsy.
Topics: Acetates; Amines; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Gabape | 1995 |
Felbamate in the treatment of acquired epileptic aphasia.
Topics: Anticonvulsants; Aphasia; Child; Electroencephalography; Epilepsy; Felbamate; Humans; Language; Male | 1995 |
Rectal administration of felbamate in a child with Lennox-Gastaut syndrome.
Topics: Administration, Rectal; Anticonvulsants; Child, Preschool; Epilepsy; Felbamate; Hemiplegia; Humans; | 1994 |
Criteria for use of felbamate in adult, adolescent, and child inpatients and outpatients.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsies, Parti | 1994 |
Novel antiepileptic drugs: nursing implications.
Topics: Acetates; Amines; Aminocaproates; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Approval; Drug | 1993 |
Science reporters hear wide range of recent data at 12th annual conference.
Topics: Acetates; Aged; AIDS Vaccines; American Medical Association; Amines; Animals; Anticonvulsants; beta- | 1993 |
Alternative analyses for antiepileptic drug trials.
Topics: Anticonvulsants; Bias; Clinical Trials as Topic; Data Interpretation, Statistical; Dose-Response Rel | 1993 |
From the Food and Drug Administration.
Topics: Adult; Anticonvulsants; Child; Drug Approval; Epilepsy; Felbamate; Heparin, Low-Molecular-Weight; Hu | 1993 |
[Campaign against epilepsy].
Topics: Aminocaproates; Animals; Anticonvulsants; Epilepsy; Felbamate; Humans; Lamotrigine; Phenylcarbamates | 1993 |
Effects of felbamate and other anticonvulsant drugs in two models of status epilepticus in the rat.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsy; Felbam | 1993 |
New antiepileptic medications.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Dr | 1995 |
Felbamate levels in patients with epilepsy.
Topics: Adolescent; Anorexia; Anticonvulsants; Child; Child, Preschool; Chromatography, High Pressure Liquid | 1996 |
Felbamate-induced headache.
Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Anticonvulsants; Dose-Response Relationship, Drug | 1996 |
Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).
Topics: Adolescent; Anticonvulsants; Brain Damage, Chronic; Child; Child Behavior Disorders; Child, Preschoo | 1995 |
Weight loss in patients taking felbamate.
Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Child; Epilepsy; Felbamate; Humans; Middle Aged; Ph | 1995 |
Anticonvulsant effect of felbamate in the pentylenetetrazole kindling model of epilepsy in the rat.
Topics: Animals; Anticonvulsants; Epilepsy; Felbamate; Kindling, Neurologic; Male; Pentylenetetrazole; Pheny | 1996 |
Gabapentin interaction with felbamate.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Interactions; Epilepsy; | 1996 |
Psychiatric effects of felbamate.
Topics: Anticonvulsants; Epilepsy; Felbamate; Humans; Phenylcarbamates; Propylene Glycols; Substance Withdra | 1997 |
New treatment options for epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose; Gabap | 1997 |
Felbamate: 1997 update.
Topics: Anemia, Aplastic; Anticonvulsants; Drug Approval; Epilepsy; Felbamate; Humans; Liver Failure; Phenyl | 1997 |
Does antiepileptic therapy affect immune response?
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbama | 1998 |
Changes of the EEG paroxysmal pattern during felbamate therapy in Lennox-Gastaut syndrome: a case report.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Carbamazepine; Clobazam; Drug Therapy, | 1998 |
Male infertility: possible association with valproate exposure.
Topics: Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Felbamate; Female; Humans; Infertility, | 1999 |
Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
Topics: Anticonvulsants; Epilepsy; Felbamate; Humans; Phenylcarbamates; Propylene Glycols | 1999 |
Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids.
Topics: Acetylcysteine; Aldehydes; Animals; Anticonvulsants; Carbamates; Chromatography, High Pressure Liqui | 1999 |
The use of felbamate in the treatment of patients with intractable epilepsy.
Topics: Anticonvulsants; Epilepsy; Felbamate; Humans; Phenylcarbamates; Propylene Glycols | 2000 |
[Positive effect of falbamate therapy in a boy with refractory epilepsy].
Topics: Anticonvulsants; Child; Epilepsy; Felbamate; Humans; Phenylcarbamates; Propylene Glycols; Severity o | 2000 |
[Preliminary assessment of felbamate effect on the cerebral bioelectrical activity in children with refractory epilepsy].
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy; Felbamate; F | 2000 |
Re: Mazarati et al. "...clinically available [antiepileptic drug] with a moderate affinity for the glycine site of the N-methyl-D-aspartate (NMDA) receptor".
Topics: Anticonvulsants; Epilepsy; Felbamate; Glycine; Humans; N-Methylaspartate; Phenylcarbamates; Propylen | 2000 |
[Clinical utilization of new anti-epileptic agents].
Topics: Acetates; Amines; Anemia, Aplastic; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dru | 2000 |
Felbamate urolithiasis.
Topics: Adolescent; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epilepsy; | 2001 |
The long-term use of felbamate in children with severe refractory epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsy; Felbamate; Female; Follow-Up | 2001 |
Mechanisms of action of new antiepileptic drugs.
Topics: Acetamides; Acetates; Amines; Aminocaproates; Aminopyridines; Anti-Anxiety Agents; Anticonvulsants; | 1989 |